A brief history of de novo protein design: minimal, rational, and computational
DN Woolfson - Journal of Molecular Biology, 2021 - Elsevier
Protein design has come of age, but how will it mature? In the 1980s and the 1990s, the
primary motivation for de novo protein design was to test our understanding of the …
primary motivation for de novo protein design was to test our understanding of the …
Opportunities and challenges in design and optimization of protein function
The field of protein design has made remarkable progress over the past decade. Historically,
the low reliability of purely structure-based design methods limited their application, but …
the low reliability of purely structure-based design methods limited their application, but …
Coengineering specificity, safety, and function into T cells for cancer immunotherapy
GMP Giordano Attianese, S Ash… - Immunological …, 2023 - Wiley Online Library
Adoptive T‐cell transfer (ACT) therapies, including of tumor infiltrating lymphocytes (TILs)
and T cells gene‐modified to express either a T cell receptor (TCR) or a chimeric antigen …
and T cells gene‐modified to express either a T cell receptor (TCR) or a chimeric antigen …
Rational design of chemically controlled antibodies and protein therapeutics
Protein-based therapeutics, such as monoclonal antibodies and cytokines, are important
therapies for various pathophysiological conditions such as oncology, autoimmune …
therapies for various pathophysiological conditions such as oncology, autoimmune …
CAR T cells targeting the ganglioside NGcGM3 control ovarian tumors in the absence of toxicity against healthy tissues
E Cribioli, GMP Giordano Attianese, G Coukos… - Frontiers in …, 2022 - frontiersin.org
Chimeric antigen receptor (CAR) T cells have emerged as a powerful immunotherapeutic
tool against certain hematological malignancies but a significant proportion of patients either …
tool against certain hematological malignancies but a significant proportion of patients either …